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Introduction
The auditory brainstem response (ABR) is used to 
delineate the auditory status of infants and children who 
are unwilling or unable to cooperate for developmentally 
appropriate behavioral test procedures or to confirm 
behavioral test findings obtained when a hearing loss is 
suspected. ABRs are bioelectric signals generated by 
the auditory nerve and units in the brainstem in response 
to auditory stimuli. The ABR is an onset response and 
requires neural synchrony in order to effectively record a 
response from electrodes which are placed on the scalp. 
ABR testing is a non-invasive procedure but requires the 
patient to remain quiet and relaxed for approximately 45 
to 60 minutes. Sedation is widely used to complete ABR 
testing for children who are not able to sleep naturally 
or remain sufficiently quiet for the duration of testing 
(American Academy of Audiology, 2012). Infants and 
older children with developmental disabilities, behavior 
disorder, autism, or intellectual disabilities often require 
sedation for successful completion of ABR testing. Using 
general anesthesia will achieve an adequate state for 
testing; however, the testing facility must arrange for 
anesthesiology, which may introduce delays in early 
identification of hearing loss. Consequently, use of 
sedation or general anesthesia could compromise 
adherence with Joint Committee on Infant Hearing 
Guidelines for early detection and management of hearing 
loss (Joint Committee on Infant Hearing, 2007). General 
anesthesia also introduces health risks such as respiratory 
and cardiac complications (Jenkins & Baker, 2003).
There are alternatives to general anesthesia for obtaining 
threshold-finding ABR results in infants and young 
children. For example, several studies have reported on 
the efficacy of melatonin as an alternative to sedation 
2017; 2(2): 10-16
Abstract: Sedation is widely used for auditory brainstem response (ABR) testing for infants or young children who 
are unable to sleep or remain adequately quiet for testing. Because chloral hydrate is no longer readily available, 
dexmedetomidine has been proposed as an alternative medicinal agent to achieve moderate levels of sedation without 
risk of respiratory depression. The purpose of the study was to assess the effectiveness of dexmedetomidine in terms 
of the completeness of the audiologic data obtained in achieving moderate levels of sedation for auditory brainstem 
response testing. A retrospective chart review was conducted on 99 patients at Kennedy Krieger Institute. Participants 
were administered either chloral hydrate or dexmedetomidine prior to ABR testing. Effectiveness was defined as 
having obtained thresholds for click and tone burst stimuli centered at 500, 2000, and 4000 Hz for both ears. Complete 
audiological data were obtained on 92.2% of patients sedated with dexmedetomidine whereas complete audiological data 
were obtained on 91% of patients sedated with choral hydrate in a period prior to the use of dexmedetomidine. It was 
concluded that dexmedetomidine is as effective as chloral hydrate in producing an appropriate state for sedated auditory 
brainstem response testing. 
Key Words: dexmedetomidine, sedation, auditory brainstem response 
Acronyms: ABR = Auditory Brainstem Response; IHS = Intelligent Hearing Systems; KKI = Kennedy Krieger Institute; 
MRI = Magnetic Resonance Imaging
Correspondence concerning this article should be addressed to: Joseph P. Pillion, PhD, Kennedy Krieger Institute, 
Department of Audiology, 801 North Broadway, Baltimore, MD 21205. Fax: 443-923-3224;  
Email: Pillion@kennedykrieger.org
11
for ABR testing (Guerlain et al., 2016; Marseglia et al., 
2015; Schmidt, Knief, Deuster, Matulat, & am Zehnhoff-
Dinnesen, 2007) and other procedures in children typically 
requiring the use of sedation (Marseglia et al., 2015). The 
efficacy of melatonin was assessed in a large sample 
of 250 children assessed with both click and tone burst 
stimuli in notched noise (Schmidt et al., 2007). Although 
the use of melatonin significantly reduced the need for 
general anesthesia by more than 80%, thresholds for 
a click, and three or more tone burst stimuli were only 
obtained in 57% of children assessed with melatonin-aided 
sleep (Schmidt et al., 2007). However, success rates were 
markedly better for children less than one year of age than 
for older children (Schmidt et al., 2007). More recently, 
use of melatonin was assessed in 56 children from 1 
year to 14.5 years who were administered ABR testing 
with a protocol that included only thresholds for click 
stimuli (Guerlain et al., 2016). The click-evoked ABR was 
completed among 43 patients. In the patients successfully 
tested, the mean delay to achieving sleep was 35 minutes 
and the mean duration of sleep only 23 minutes (Guerlain 
et al., 2016).
Another alternative to sedation use for ABR testing 
involves using sophisticated response collection 
algorithms which are more robust in the presence of 
patient-generated motion artifact (e.g., Kalman adaptive 
processing; Cone & Norrix, 2015). Kalman adaptive 
averaging has been used to improve the signal to 
noise ratio in noisy recordings and has been shown to 
reduce the averaging time needed for resolution of ABR 
responses by 75% as compared to more traditional 
averaging techniques (Chan, Lam, Poon, & Qiu, 1995). 
In the presence of motoric activity, Kalman-weighted 
averaging coupled with in situ bio-amplifiers results in ABR 
threshold estimates that are 6 to 7 dB lower than when 
conventional ABR averaging methods are used (Cone 
& Norrix, 2015). It was suggested that the methodology 
may make it possible to test some infants in an awake 
state without the associated added costs and potential 
delays inherent with use of sedation or general anesthesia 
(Cone & Norrix, 2015). The effectiveness the commercial 
application of Kalman-weighted averaging coupled with 
in situ bio-amplifiers was undertaken in 103 children who 
were administered click and tone burst evoked ABR testing 
without use of sedation (Hall, 2010). It was not possible to 
record any interpretable ABR results on 6% of the children 
(Hall, 2010). Click evoked ABR thresholds were obtained 
on 94% of children. However, the instrumentation was less 
effective in obtaining thresholds for 500 Hz (24% of Ss), 
1000 Hz (36% of Ss), 2000 Hz (40% of Ss), and 4000 Hz 
(40% of Ss) for the tone burst stimuli (Hall, 2010).
Use of conscious or moderate sedation is also 
an alternative to general anesthesia for achieving 
an adequate level of cooperation for ABR testing 
(Reynolds, Rogers, Medellin, Guzman, & Watcha, 
2016). Dexmedetomidine has been used in recent 
years to achieve moderate levels of sedation for ABR 
and other procedures (Ambi, Joshi, Ganeshnavar, & 
Adarsh, 2012; Reynolds, Rogers, Medellin et al., 2016). 
Dexmedetomidine achieves rapid onset of sedation 
effects with a relatively short half-life which lends itself 
to non-invasive outpatient procedures such as magnetic 
resonance imaging (MRI) and ABR studies (Phan & 
Nahata, 2008). In addition, intranasal dexmedetomidine 
has some potentially beneficial analgesic and anxiolytic 
side effects which might be significant for some patients 
(Phan & Nahata, 2008). Use of dexmedetomidine was 
approved by the Food and Drug Administration for use in 
non-intubated adult patients in 2008 and has been used in 
pediatric applications for procedures which are minimally 
invasive off-label since that time (Shukry & Miller, 2010). 
It is not a controlled substance (Drug Enforcement 
Administration, 2017). Dexmedetomidine is an anxiolytic 
and sedative medication which is used in the intensive 
care setting for light to moderate sedation (Phan & Nahata, 
2008). It is an agonist of alpha2-adrenergic receptors in 
certain parts of the brain and is similar to the medication 
clonidine, which is often prescribed in children with 
attention deficit hyperactivity disorder (Sallee, Connor, & 
Newcorn, 2013). It can provide sedative effects without 
risk of respiratory depression, unlike other commonly 
used sedatives such as propofol, fentanyl, and midazolam 
(Phan & Nahata, 2008). Dexmedetomidine is absorbed 
through the olfactory mucosa, allowing for intranasal 
administration (Iirola et al., 2011). Dexmedetomidine 
does have potential adverse side effects which include 
lowered blood pressure and decreased oxygen in tissues 
or blood (Cravero, Anderson, & Wolf, 2015). Although 
use of dexmedetomidine has been shown to reduce heart 
rate and blood pressure, vital signs remain within safe 
physiologic limits and no serious adverse effects have 
been reported (Surendar, Pandey, Saksena, Kumar, & 
Chandra, 2014). Intranasal dexmedetomidine produces 
considerably less impact upon respiration than alternative 
forms of sedation and is regarded as safer than chloral 
hydrate or other alternative drugs used to achieve 
conscious sedation (Cozzi, Norbedo, & Barbi, 2017). 
Intranasal dexmedetomidine has been used to achieve 
moderate levels of sedation for MRI studies (Ambi, 
Joshi, Ganeshnavar, & Adarsh, 2012; Zhang et al., 2016) 
and for electroencephalogram studies (Baier, Mendez, 
Kimm, Velazquez, & Schroeder, 2016) as well as auditory 
brainstem response measurements in children (Baier 
et al., 2016; Reynolds, Rogers, Capehart, Manyang, & 
Watcha, 2016; Reynolds, Rogers, Medellin et al., 2016).
Moderate sedation is an alternative to general anesthesia 
which requires less intensive medical supervision 
and can be undertaken outside of an operating room 
environment. Chloral hydrate was widely used to achieve 
moderate sedation for ABR studies but is no longer used 
for several reasons. Respiratory depression, vomiting, 
and paradoxical hyperactivity are potential side effects of 
chloral hydrate sedation (Greenberg, Faerber, & Aspinall, 
1991). Complications such as vomiting, hyperactivity, 
or rash have been reported in 20.7% of children tested 
with chloral hydrate (Avlonitou et al., 2011). Additionally, 
chloral hydrate is often administered orally, which requires 
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cooperation of the patient to swallow the medication 
in order to ensure accurate dosing. There is also a 
heightened risk of respiratory compromise with the 
possibility of neurologic injury in patients with certain 
conditions (e.g., cerebral palsy, obstructive sleep apnea, 
hypertrophic tonsils and adenoids, and tracheostomy; 
Phan & Nahata, 2008). Finally, chloral hydrate is difficult to 
obtain, as the sole remaining pharmaceutical manufacturer 
in the United States has ceased production of the 
medication (Mason, 2014). Choral hydrate is still in use in 
other countries (Valenzuela et al., 2016). However, it has 
not been recommended for use in pediatric sedation for 
a number of years (Cote, Karl, Notterman, Weinberg, & 
McCloskey, 2000). Use of chloral hydrate is now banned 
in France and Italy due to evidence of carcinogenicity and 
genotoxicity (Cozzi et al., 2017).
In anticipation that chloral hydrate would no longer be 
available, a team with representatives from pediatrics, 
pediatric anesthesiology, nursing, and pharmacy 
considered available medications for moderate sedation 
and selected intranasal dexmedetomidine as the 
most suitable option for the Kennedy Krieger Institute 
(KKI) because of its safety profile, lack of respiratory 
depression effects, and ease of administration. Intranasal 
dexmedetomidine has been shown to achieve moderate 
levels of sedation in significantly less time than chloral 
hydrate with no occurrences of hypoxemia (Reynolds, 
Rogers, Medellin et al., 2016; Zhang et al., 2016). First 
dose success rates for intranasal dexmedetomidine have 
been shown to be higher than those achieved previously 
in patients sedated with chloral hydrate (Baier et al., 
2016). The injectable formulation of dexmedetomidine 
is administered into the nose using an atomizer. This 
method of administration has been used safely in 
previous investigations evaluating the sedative effects of 
dexmedetomidine in children (Baier et al., 2016; Cravero et 
al., 2015; Reynolds, Rogers, Medellin et al., 2016). Onset 
of sedation is typically about 20 to 30 minutes and lasts 60 
to 90 minutes (Reynolds, Rogers, Medellin et al., 2016).
The purpose of the present retrospective study was to 
compare the effectiveness of intranasal dexmedetomidine 
with chloral hydrate in achieving an adequate state for 
the auditory brainstem response testing protocol used at 
Kennedy Krieger Institute. Consecutive medical records 
were examined with no attempt made to control for subject 
variables. This protocol requires obtaining responses to 
click stimuli and tone bursts centered at 500, 2000, and 
4000 Hz for both ears. The tone bursts were presented 
in the background of notched noise. Tympanometry 
and measurements of otoacoustic emissions are 
also performed. Few studies have investigated the 
effectiveness of intranasal dexmedetomidine for sedation 
in ABR studies (Reynolds, Rogers, Medellin et al., 
2016). No studies have quantified the effectiveness of 
dexmedetomidine for a range of stimulus conditions, 
including both click stimuli and frequency specific tone 
burst stimuli. Previous studies investigating the efficiency 
of intranasal dexmedetomidine in sedation for ABR studies 
have included only a single stimulus condition (Baier et al., 
2016; Reynolds, Rogers, Capehart et al., 2016; Reynolds, 
Rogers, Medellin et al., 2016). Such data do not permit the 
degree, configuration, and etiology of a hearing loss to be 
determined. It is important that effectiveness of intranasal 
dexmedetomidine be evaluated for a range of stimulus 
conditions because the completeness of this data informs 
treatment decisions and the need for further evaluation 
and/or intervention.
Procedures 
This investigation was approved by the Johns Hopkins 
Medicine Institutional Review Board. A retrospective 
chart review was conducted for patients at Kennedy 
Krieger Institute who underwent sedated ABR 
testing. Data were available for 64 patients sedated 
with intranasal dexmedetomidine and 35 patients 
sedated with chloral hydrate. The subjects in the 
dexmedetomidine group ranged from 6 months of age 
to 10 years and 7 months of age (mean age = 3.30 
years). The subjects in the chloral hydrate group ranged 
in age from 7 months to 5 years and 11 months (mean 
age = 2.80 years). Sedated ABR testing is typically not 
performed on children younger than six months because 
these children are usually able to sleep without sedation 
for the duration of testing. The subjects typically had 
multiple diagnoses including speech and language 
delay, history of otitis media, behavior disorders, 
autism spectrum disorder, ADHD, global developmental 
delay, and hypotonia. All subjects were medically 
evaluated by a Kennedy Krieger Institute developmental 
pediatrician as well as by their own pediatrician to 
ensure candidacy for sedation. A sedation referral 
form, shown in Table 1, was completed by each child’s 
pediatrician prior to scheduling an appointment for a 
sedated ABR. Because dexmedetomidine lowers heart 
rate and blood pressure, it is contraindicated for use 
in children with known bradycardia, hypotension, or 
other cardiac problems. When children were screened 
for sedation, it was decided that dexmedetomidine 
would not be used in children who were taking other 
medications that lower heart rate or blood pressure. 
Dosing and response to dexmedetomidine may be 
affected if children are prescribed other alpha-2 
agonists. Guanfacine and clonidine are the two alpha-2 
agonists that are commonly prescribed. Guanfacine, 
also known as Intuniv, is approved for treatment 
of attention deficit hyperactivity disorder (ADHD). 
Clonidine can be used for treatment of ADHD and high 
blood pressure. Tizanidine is also a related medication.  
The protocol at KKI specifies that patients discontinue 
these medications for 2 weeks prior to sedation, as 
dexmedetomidine will be more effective if patients do 
not have tolerance to that class of medications.
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AEP DATE:
DOB:
KKI#:
Pertinent Past Medical History (elaborate on any Yes responses):
Any prior complications of anesthesia or sedation? [ ] yes  [ ] no
Physical Exam: Abnormal (describe)Normal (N) / Abnormal (A)
Height: Weight:
Other
Abdomen
Date/TimeProvider SignaturePrinted Name
Cardiovascular
Lungs
HEENT
and find the patient to be in his/her usual state of health and find no
contraindications to doing AEP testing under moderate sedation. 
I evaluated the above patient on 
Additional Info:
The above named patient has been referred for sedated AEP testing. Intranasal Dexmedetomidine will be administered.
Name:
Past SurgeriesAllergies (or sensitivities,especially to meds)MedicationsMedical Problem List
NoYesNoYesNo
Other neurologic problem
Cerebral palsy
Hydrocephalus/Shunt
Seizures/epilepsy
Other blood disorder
History of transfusion
Anemia
Congenital anomaly
History of:
Other heart disease
Arrhythmia
Need for SBE prophylaxis
Congenital heart disease
Other pulmonary disease
Asthma
Aspiration
Obstructive sleep apnea
History of:
Kidney disease
Liver disease
Frequent vomiting
Gastroesophageal reflux
Feeding/Swallowing problems
ENT Problems
Apnea
Premature birth
History of: Yes
Table 1 
Pre-Sedation Referral Form
Note. AEP = Auditory Evoked Potential; ENT = Ear, Nose, and Throat; HEENT = Head, Ear, Eyes, Nose, and Throat; SBE = Subacute 
Bacterial Endocarditis Prophylaxis
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Dexmedetomidine is administered through intranasal 
administration by contact with the olfactory mucosa (Iirola 
et al., 2011). This was achieved with use of a tuberculin 
syringe with an atomizer device. Guidelines promulgated 
by the Committee on Drugs of the American Academy 
of Pediatrics pertaining to dietary precautions, as well 
as monitoring and management of pediatric patients for 
conscious sedation were followed (American Academy 
of Pediatrics, 1992). Patients received an examination 
from a developmental pediatrician and a health history 
was taken along with a baseline weight and vital signs. 
Due to the possible effects of decreased blood pressure 
and pulse, the patients were monitored by a nurse 
throughout the procedure. Blood oxygen saturation 
was measured by continuous pulse oximetry. Blood 
pressure measurements were taken every 15 minutes. 
The available dosing of dexmedetomidine at KKI was in 
a concentration of 100mcg/1cc. The dosing was usually 
split between each nostril to decrease runoff and maximize 
absorptive tissue area. The ideal volume per nostril is 
0.2–0.3cc and maximum recommended dose is 0.5–1cc 
per nostril (Barclay & Lie, 2010). When administering 
small doses to younger patients, it was necessary to dilute 
dexmedetomidine to a concentration of 50mcg/1cc to allow 
adequate volume for intranasal use. On the day following 
the appointment, a telephone call was placed to each 
patient’s parent/guardian to inquire about recovery and any 
adverse effects. Based on continued evaluation of patient 
response intranasal dexmedetomidine at KKI, the current 
dosing protocol is to give 2 mcg/kg for the initial dose. 
Previous research provides evidence that a 2 mcg/kg dose 
is effective for sedation in pediatric populations (Yuen et 
al., 2012). If the patient is not sufficiently sedated by 25 
minutes after the initial dose, an additional 1 mcg/kg dose 
of intranasal dexmedetomidine is given. A third dose of 1 
mcg/kg is given if the patient remains awake 25 minutes 
after the second dose. Dosing remains individualized 
but this protocol has provided consistent results for the 
majority of our sedated auditory evoked potential and 
electroencephalogram procedures. The dosing for chloral 
hydrate was 75 mg/kg. When vomiting occurred with 
chloral hydrate administration, re-administration of the 
medication was required. In some such cases, sedation 
was ineffective.
After ensuring the patient had reached an adequate state 
for testing, ABR data were collected using an Intelligent 
Hearing System’s (IHS) Smart Evoked Potential System. 
The skin was prepped using NuPrep solution and 
standard EEG disk electrodes were affixed to the following 
locations: Fpz (ground), Fz (non-inverting), A1 and A2 
(inverting for ipsilateral and contralateral ear). Click stimuli 
and tone burst stimuli centered at 500, 2000, and 4000 Hz 
were presented to each ear via insert earphones. Notched 
noise was used for the tone burst stimuli. If any degree of 
hearing loss was present, testing by bone conduction was 
completed with the delivery of appropriate contralateral 
masking noise. Tympanometry and measurements of 
otoacoustic emissions were also performed following  
ABR testing.
Results 
Complete audiological data was defined as having 
obtained thresholds for click stimuli and for tone burst 
stimuli centered at 500, 2000, and 4000 Hz for both 
the left and the right ear. Complete audiological data 
were obtained on 92.2% of patients sedated with 
dexmedetomidine. Complete audiological data were 
obtained on 91% of patients sedated with choral 
hydrate. A chi-square analysis revealed that there was 
no significant difference in outcome between the two 
forms of sedation (χ2(1, N = 99) = 0.0175, p = 0.89). 
Complete data were obtained for at least one ear on all 
patients.
Table 2 
Participant Demographics
Most of the children required two (50%) or three doses 
(20%) of dexmedetomidine. Only 30% of patients 
sedated with a single dose. The average times before 
sedation were 25 minutes, 39.4 minutes, and 57.5 
minutes for patients requiring 1, 2 or 3 doses of 
dexmedetomidine respectively.
The mean age for patients sedated with 
dexmedetomidine who were adequately sedated with 
only one dose was 3 years. The range of ages of 
children receiving a single dose was 6 months to 10.5 
years. The mean age for those receiving more than 1 
dose was 4.4 years, with a range of 9 months to 10.6 
years. The mean total examination time across all 
participants who received dexmedetomidine was 53.1 
minutes. No patients in the dexmedetomidine group 
required supplemental oxygen. All patients returned 
to baseline functioning and were discharged on the 
same day as the procedure. No patients receiving 
dexmedetomidine experienced nausea or vomiting that 
was either observed or reported after discharge.
 
Discussion 
The results of this investigation indicate that intranasal 
dexmedetomidine is as effective as chloral hydrate 
in achieving moderate levels of sedation for ABR 
testing. No sentinel events occurred due to the use of 
dexmedetomidine. None of the adverse side effects 
associated with chloral hydrate including vomiting, 
hyperactivity, or respiratory depression occurred during 
Not effectiveEffective
9%
(n = 3)
8%
(n = 5)
91%
(n = 32)
92%
(n = 59)
Dexmedetomidine
(n = 64)
Sedation Type
Sedation Type:
Chloral Hydrate
(n = 35)
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the use of intranasal dexmedetomidine. Intranasal 
dexmedetomidine was noted by all members of the 
team to be far easier to administer than oral chloral 
hydrate. Intranasal administration requires minimal 
cooperation from the patient. A team member or family 
member gently tilts the patient’s head posteriorly and 
immobilizes the head while the nasal spray is being 
administered. The patient remains in this position for 
approximately 20 seconds and can then resume normal 
activities. In contrast, administration of chloral hydrate 
required staff to induce patients to swallow an ill-tasting 
medication which was for some patients difficult to 
achieve without uncertain amounts of the medication 
being spit out or vomited. This study supports previous 
studies suggesting that intranasal dexmedetomidine is 
an appropriate alternative to chloral hydrate or general 
anesthesia for ABR testing for most patients (Baier et 
al., 2016; Reynolds, Rogers, Medellin et al., 2016). 
The effectiveness of dexmedetomidine appears to be 
superior to that of alternatives such as administration 
of melatonin (Schmidt et al., 2007) or use of Kalman 
averaging (Hall, 2010) which previous studies have 
shown to be less effective than results achieved in the 
present study.
Several limitations of the present investigation were 
noted. The retrospective design of the investigation did 
not allow for variables such as patient age, the presence 
of health conditions, or time of testing to be controlled or 
systematically examined. Additionally, the participants in 
this investigation were limited to the patients who chose 
to seek care at KKI. Use of dexmedetomidine requires 
medical monitoring and continuous physiological 
monitoring with the attendant expense just as when 
using chloral hydrate. Further investigations should be 
completed to include larger sample sizes and diverse 
populations. As noted earlier, there are alternatives to 
moderate sedation or general anesthesia for obtaining 
threshold-finding ABR results in infants and young 
children. For example, several studies have reported on 
the efficacy of melatonin as an alternative to sedation 
for ABR testing with few adverse side effects (Guerlain 
et al., 2016; Marseglia et al., 2015; Schmidt et al., 
2007). Future research comparing the effectiveness and 
safety of melatonin to dexmedetomidine for obtaining 
ABR measurements should be completed to determine 
if either medication is more effective. Additionally, 
Kalman adaptive averaging has been used to improve 
the signal to noise ratio in noisy recordings and has 
been shown to reduce the averaging time needed for 
resolution of ABR responses by 75% as compared to 
more traditional averaging techniques (Chan et al., 
1995). Incorporating the use of this technology may 
improve the effectiveness of sedation medication by 
shortening the length of test time and allowing a greater 
amount of patient movement. Future investigations 
could evaluate the effectiveness of dexmedetomidine 
and/or other sedation medications while incorporating 
this signal averaging technology.
Conclusions 
Measurement of ABRs is an important tool for the 
delineation of hearing status, as the ABR allows the 
auditory status of infants and children to be assessed 
when other methods are inappropriate or unsuccessful. 
Although sedation is commonly used for ABR testing, 
no medication has yet replaced chloral hydrate as the 
clinical standard since its large-scale production was 
ceased. The results of this study suggest that intranasal 
dexmedetomidine is an acceptable form of sedation for 
ABR testing in pediatric patients. Complete audiological 
data was achieved in 92% of patients. This was 
accomplished without any of the patients experiencing 
breathing difficulty, vomiting, or other sentinel effects 
during or after the procedure. Dexmedetomidine 
demonstrated similar rates of effectiveness as chloral 
hydrate with fewer side effects. This study contributes 
to the body of literature supporting the use of 
dexmedetomidine for clinical use in facilities performing 
sedated ABR measurements.
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